-

Amylyx Pharmaceuticals to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will present at the following upcoming conferences, which are being conducted in-person:

  • Guggenheim 2nd Annual Healthcare Innovation Conference: Fireside chat on Monday, November 10, 2025, at 4:30pm ET in Boston, Massachusetts
  • 8th Annual Evercore Healthcare Conference: Fireside Chat on Tuesday, December 2, 2025, at 8:20am ET in Coral Gables, Florida
  • Citi's 2025 Global Healthcare Conference: Fireside Chat on Wednesday, December 3, 2025, at 4:00pm ET in Miami, Florida

A live webcast of each fireside chat can be accessed under “Events and Presentations” in the Investor section of the Company’s website, https://investors.amylyx.com/events-presentations, and will be available for replay for 90 days following the event.

About Amylyx Pharmaceuticals

At Amylyx, our mission is to usher in a new era of treating diseases with high unmet needs. Where others see challenges, we see opportunities that we pursue with urgency, rigorous science, and unwavering commitment to the communities we serve. We are currently focused on three investigational therapies across several neurodegenerative and endocrine diseases in which we believe they can make the greatest impact. For more information, visit amylyx.com and follow us on LinkedIn and X. For investors, please visit investors.amylyx.com.

Contacts

Media
Amylyx Media Team
+1 (857) 320-6191
amylyxmediateam@amylyx.com

Investors
Lindsey Allen
Amylyx Pharmaceuticals, Inc.
+1 (857) 320-6244
Investors@amylyx.com

Amylyx Pharmaceuticals, Inc.

NASDAQ:AMLX

Release Summary
Amylyx Pharmaceuticals to Present at Upcoming Investor Conferences
Release Versions
$Cashtags

Contacts

Media
Amylyx Media Team
+1 (857) 320-6191
amylyxmediateam@amylyx.com

Investors
Lindsey Allen
Amylyx Pharmaceuticals, Inc.
+1 (857) 320-6244
Investors@amylyx.com

Social Media Profiles
More News From Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) will announce topline results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026. Amylyx’s senior management team will host a conference call and audio webcast at 8:00 a.m. ET. To access the conference call, please dial +1 (888) 880-3330 (U.S. & Canada) or +1 (646) 357-8766 (international) at least 10 minutes prior to the start time...

Amylyx Pharmaceuticals Reports Second Quarter 2026 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals Reports Second Quarter 2026 Financial Results...

Amylyx Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026...
Back to Newsroom